SN
SNBIF.US SanBio Company Limited
- Market cap
- USD 1.28B
- P/E
- -
- P/B
- 135.51x
- ROE
- -30.6%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jul 2026.
Is SNBIF.US undervalued?
Graham numberThe Graham number of SanBio Company Limited cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
SanBio Company Limited fundamental analysis
No fundamental analysis for SanBio Company Limited yet.
SanBio Company Limited stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About SanBio Company Limited
SanBio Company Limited engages in the development, production, and sale of regenerative cell medicines for the central nervous system in Japan and the United States. It develops SB623 that has completed a phase 2 clinical trial to treat traumatic brain injury. The company's research pipeline products also comprise SB623 for chronic disease, age-related macular degeneration, retinitis pigmentosa, spinal cord injury, Parkinson's disease, Alzheimer's disease, etc.; SB618 to tre…
Full company profileSanBio Company Limited financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jul 31, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
SanBio Company Limited annual financial statements (JPY; K = thousand, M = million, B = billion, T = trillion)
| Item | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 949M | 490M | 742M | 447M | 22.9M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 932M | 490M | 741M | 447M | - | - | - | - | - | - | - |
| Operating Income | -1.93B | -4.38B | -3.73B | -5.49B | -5.80B | -6.62B | -7.90B | -4.54B | -3.52B | -3.79B | -3.82B |
| EBITDA | - | - | -2.85B | -5.07B | -3.09B | -4.38B | -4.65B | -2.52B | -2.99B | -4.25B | -3.42B |
| Net Income | -1.84B | -3.94B | -2.92B | -5.16B | -3.39B | -4.68B | -5.56B | -2.64B | -2.88B | -3.84B | -3.58B |
| EPS | - | - | -59 | -100 | -65 | -90 | -90 | -39 | -41 | -49 | -46 |
| Balance Sheet | |||||||||||
| Total Assets | 6.29B | 5.19B | 14.0B | 15.6B | 13.3B | 5.51B | 7.05B | 5.05B | 3.45B | 15.6B | 13.6B |
| Total Liabilities | 1.70B | 4.34B | 5.07B | 4.68B | 4.99B | 3.48B | 2.62B | 2.25B | 1.68B | 2.02B | 1.92B |
| Shareholders' Equity | 4.60B | 851M | 8.91B | 10.9B | 8.35B | 2.04B | 4.43B | 2.79B | 1.76B | 13.6B | 11.7B |
| Cash & Short-term Investments | 0.00 | 0.00 | 0.00 | 13.6B | 12.5B | 4.56B | 6.73B | 4.45B | 2.92B | 15.1B | 12.7B |
| Cash Flow | |||||||||||
| Operating Cash Flow | -1.80B | -1.91B | -3.97B | -5.72B | -5.22B | -6.55B | -7.43B | -4.77B | -3.60B | -3.76B | - |
| Capital Expenditure | 96.0M | 32.0M | 6.00M | 95.0M | 96.0M | 42.0M | 7.91M | 55.0M | 4.89M | 32.8M | 0.00 |
| Free Cash Flow | - | - | -3.97B | -5.82B | -5.35B | -6.60B | -7.44B | -4.82B | -3.61B | -3.79B | - |
| Ratios | |||||||||||
| ROE | -39.9% | -463.0% | -32.8% | -47.2% | -40.5% | -229.9% | -125.5% | -94.7% | -163.5% | -28.2% | -30.6% |
| ROA | -29.2% | -75.9% | -20.9% | -33.1% | -25.4% | -84.9% | -78.9% | -52.4% | -83.6% | -24.6% | -26.3% |
| Net Profit Margin | -193.4% | -804.1% | -393.8% | -1,153.3% | -14,797.1% | - | - | - | - | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
SanBio Company Limited dividends
SanBio Company Limited has not paid dividends in the last 9 fiscal years.
Who owns SanBio Company Limited
- Insiders 24.63%
- Institutions 6.86%
- Public & others 68.51%
- Shares outstanding 78.1M
- Free float 59.1M
SanBio Company Limited company profile
- Company name
- SanBio Company Limited
- Ticker
- SNBIF.US
- Exchange
- USA Stocks
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 33
- Fiscal year end
- January
- Address
- St. Luke Tower, Tokyo, Japan, 104-0044
- Phone
- 81 3 6264 3481
- Website
- sanbio.com
About SanBio Company Limited
SanBio Company Limited engages in the development, production, and sale of regenerative cell medicines for the central nervous system in Japan and the United States. It develops SB623 that has completed a phase 2 clinical trial to treat traumatic brain injury. The company's research pipeline products also comprise SB623 for chronic disease, age-related macular degeneration, retinitis pigmentosa, spinal cord injury, Parkinson's disease, Alzheimer's disease, etc.; SB618 to treat peripheral nerve damage; SB308 for muscular dystrophy disease; MSC1 for cancer; and MSC2 for inflammatory disease and optic neuritis. The company was founded in 2001 and is headquartered in Tokyo, Japan.
SanBio Company Limited management
8- Mr. Toru KawanishiCo-Founder & Executive Chairman · born 1967
- Mr. Keita Mori MBACo-Founder, President, Executive Officer, CEO & Representative Director · born 1967
- Mr. Yoshihiro KakutaniCorporate Officer of Management Administration
- Mr. Naoki TsukaharaSenior Corporate Officer
- Mr. Tetsuya IsonoCorporate Officer & Head of Production
- Mr. Soyoku NobeyamaCorporate Officer, Head of Japan Regulatory Affairs & Quality Compliance Japan
- Mr. Dai ChidaSenior Scientific Advisor
- Munetaka NobeyamaExecutive Officer, Head of Reliability Assurance & Regulatory Affairs Division